Mutations in the Nrf2 pathway genes appear to be specific to pRCC, but re-analysis of TCGA ccRCC data (details not shown) using Intogen does shows that a small, but significant proportion (~2%) has mutations in NFE2L2 (ref. 18). This evidence concerns the gene NFE2L2 and nonpapillary renal cell carcinoma.